FindTrial
Sign In

Effect of Switching from Telmisartan, Valsartan, Olmesartan or Losartan to Candesartan on Morning Hypertension

Effect of Switching from Telmisartan, Valsartan, Olmesartan or Losartan to Candesartan on Morning Hypertension - Effect of Switching from Telmisartan, Valsartan, Olmesartan or Losartan to Candesartan on Morning Hypertension

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000007682
Enrollment
60
Registered
2012-04-07
Start date
2009-10-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

antihypertensives

Sponsors

Department of Cardiovascular Science and Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) aged 20 to 70 years old; 2) hypertensive patients without adequately controlled (≥ 135/85 mmHg in the morning); and 3) treated with the standard doses of ARBs except candesartan (losartan 50 mg, valsartan 80 mg, telmisartan 40 mg, or olmesartan 20 mg)

Exclusion criteria

Exclusion criteria: 1) severe hypertension (≥ 180/110 mmHg); 2) malignant disease; 3) serious renal dysfunction (serum creatinine ≥ 2.0 mg/dL); and 4) secondary hypertension

Design outcomes

Primary

MeasureTime frame
the achievement rate of target BPs (≤ 135/85 mmHg in the morning and ≤ 140/90 mmHg at office)—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026